跳至主要内容
临床试验/CTRI/2021/02/031231
CTRI/2021/02/031231已完成2 期

A Prospective Open labelled non randomized phase II clinical study on KUPPAIMENI CHOORANAM in the management of IRAIPPU IRUMAL(BRONCHIAL ASTHMA)

Government Siddha Medical College and Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年2月4日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
2.Recurrent attacks of dyspnoea

研究概览

简要总结

The study is a Prospective  Open  labelled  phase  II non randomized  clinical  study  to evaluate  the therapeutic  efficacy of  KUPPAIMENI  CHOORANAM  in the  management  of IRAIPPU IRUMAL (BRONCHIAL ASTHMA). The trial drug  will  be  administered  at the dose of 30mg/Kg/BW /twice a day(orally) A/F 45 days along with Hot water as adjuvant in 60 patients. The trial  period  of 12 months will be carried out in Government  Siddha  Medical  College  and  Hospital, Palayamkottai, Tirunelveli, Tamilnadu. The primary outcome  will be  evaluation  of  therapeutic  efficacy  of  trial  drug  KUPPAIMENI  CHOORANAM. The  secondary  outcome  will be the evaluations of Siddha diagnostic parameters, assessment  of safety  profile  of  trial  drug,assessment  of pharmacological  and biochemical  parameters  of  trial  drug. In case  of  any  adverse  events (AE) is noticed and it will be referred to pharmacovigilance department  of SCRI.Further management  of patients will be given  in OPD facility.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • •1.Patient with the symptoms of dry cough, recurrent attacks of dyspnoea,hoarseness of voice,tightness of chest,profuse sweating and wheezing 2.History of allergens, climatic changes 3.Patients who are willing to take radiological investigation and provide blood for lab investigation.

排除标准

  • •1.Cardiac Diseases 2.Chronic allergic bronchitis 3.Tuberculosis 4.COPD 5.Pregnancy and Lactating mother 6.Restrictive airway disease 7.Status Asthmaticus 8.Systemic Hypertension 9.Autoimmune Diseases 10.Drugs and Chemicals.

结局指标

主要结局

2.Recurrent attacks of dyspnoea

时间窗: 45 days

6.Wheezing

时间窗: 45 days

If during treatment or after treatment reduction of the following symptoms

时间窗: 45 days

1.Dry cough

时间窗: 45 days

3.Hoarseness of voice

时间窗: 45 days

4.Tightness of chest

时间窗: 45 days

5.Profuse sweating

时间窗: 45 days

次要结局

  • 1.To evaluate the pharmacological activities(2.Study about the prevalence of Iraippu Irumal in relation between diet and life styles)

研究者

发起方
Government Siddha Medical College and Hospital
申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验